Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Stevanato Group SpA (STVN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: STVN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $28.63
1 Year Target Price $28.63
| 6 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -9.64% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.05B USD | Price to earnings Ratio 38.89 | 1Y Target Price 28.63 |
Price to earnings Ratio 38.89 | 1Y Target Price 28.63 | ||
Volume (30-day avg) 11 | Beta 0.55 | 52 Weeks Range 17.07 - 28.00 | Updated Date 08/15/2025 |
52 Weeks Range 17.07 - 28.00 | Updated Date 08/15/2025 | ||
Dividends yield (FY) 0.24% | Basic EPS (TTM) 0.57 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate 0.1 | Actual 0.11 |
Profitability
Profit Margin 11.75% | Operating Margin (TTM) 15.03% |
Management Effectiveness
Return on Assets (TTM) 5.2% | Return on Equity (TTM) 9.89% |
Valuation
Trailing PE 38.89 | Forward PE 35.46 | Enterprise Value 6417972454 | Price to Sales(TTM) 5.29 |
Enterprise Value 6417972454 | Price to Sales(TTM) 5.29 | ||
Enterprise Value to Revenue 4.79 | Enterprise Value to EBITDA 27.56 | Shares Outstanding 49691400 | Shares Floating 48894417 |
Shares Outstanding 49691400 | Shares Floating 48894417 | ||
Percent Insiders 1.66 | Percent Institutions 105.85 |
Upturn AI SWOT
Stevanato Group SpA
Company Overview
History and Background
Stevanato Group SpA was founded in 1949 in Italy. It started as a glass manufacturer for pharmaceutical packaging and has since expanded into integrated solutions for drug containment and delivery. Key milestones include globalization, product diversification, and strategic acquisitions to enhance its capabilities.
Core Business Areas
- Pharmaceutical Systems: Manufactures glass primary packaging (vials, ampoules, cartridges) for injectable drugs and provides related services like washing and sterilization.
- Engineering: Designs, manufactures, and sells equipment for processing pharmaceutical glass tubing into vials, ampoules, and cartridges. Also, inspection systems and assembly equipment are included.
- Analytical Services: Offers lab testing services for the pharmaceutical industry to confirm compliance with regulatory specifications for packaging materials and processes.
Leadership and Structure
Franco Stevanato is the Executive Chairman, and Marco Stevanato is the Chief Executive Officer. The company has a board of directors and operates with a functional organizational structure.
Top Products and Market Share
Key Offerings
- Competitors: Gerresheimer, Schott, SGD Pharma
- Glass Vials: High-quality glass vials for injectable drugs. They are a core product with a significant market share in the pharmaceutical packaging market. Competitors include Gerresheimer, Schott, and SGD Pharma. Market share (estimated): 20%.
- Cartridges: Cartridges for pen injectors and auto-injectors. Used for insulin and other injectable therapies. Market share (estimated): 15%. Competitors include West Pharmaceutical Services, Gerresheimer.
- Competitors: West Pharmaceutical Services, Gerresheimer
- Competitors: Becton Dickinson, Gerresheimer
- Syringes: Ready-to-use syringes with integrated safety devices. Used for vaccines and other critical drug delivery. Market share (estimated): 10%. Competitors include Becton Dickinson, Gerresheimer.
Market Dynamics
Industry Overview
The pharmaceutical packaging market is growing due to increasing demand for injectable drugs, biologics, and vaccines. Stringent regulatory requirements and the need for drug stability drive demand for high-quality packaging solutions.
Positioning
Stevanato Group SpA is a leading player in the high-value pharmaceutical packaging market. Its integrated solutions, global presence, and focus on quality provide a competitive advantage.
Total Addressable Market (TAM)
The global pharmaceutical packaging market is expected to reach $150 billion by 2028. Stevanato Group SpA is well-positioned to capture a significant share of this growing market through its focus on high-value segments like injectable drug packaging and drug delivery systems.
Upturn SWOT Analysis
Strengths
- Integrated solutions (packaging and equipment)
- Strong reputation for quality
- Global presence
- Long-standing relationships with major pharmaceutical companies
- Focus on high-value segments (injectables, biologics)
Weaknesses
- Dependence on pharmaceutical industry cycles
- High capital expenditure requirements
- Exposure to raw material price fluctuations
- Geographic concentration of manufacturing facilities
Opportunities
- Growing demand for biologics and biosimilars
- Increasing adoption of self-administration drug delivery devices
- Expansion into emerging markets
- Strategic acquisitions to expand product portfolio
- Development of new packaging technologies
Threats
- Intense competition from larger players
- Stringent regulatory requirements and potential for non-compliance
- Economic slowdown in key markets
- Disruptions in supply chain
- Erosion of intellectual property rights
Competitors and Market Share
Key Competitors
- West Pharmaceutical Services (WST)
- Gerresheimer AG (GXI.DE - note: not US listed. No symbol)
- Becton, Dickinson and Company (BDX)
Competitive Landscape
Stevanato Group SpA competes with larger players in the pharmaceutical packaging market. Its advantages include its integrated solutions, focus on high-value segments, and strong reputation for quality. Disadvantages include its smaller size and dependence on the pharmaceutical industry.
Major Acquisitions
Balda AG
- Year: 2016
- Acquisition Price (USD millions): 136.5
- Strategic Rationale: Expanded capabilities in plastic components for drug delivery devices.
Growth Trajectory and Initiatives
Historical Growth: Stevanato Group SpA has experienced strong growth in recent years driven by demand for its pharmaceutical packaging and equipment solutions.
Future Projections: Analysts project continued growth for Stevanato Group SpA driven by the growth of the pharmaceutical industry and its focus on high-value segments.
Recent Initiatives: Recent initiatives include investments in capacity expansion, new product development, and strategic acquisitions.
Summary
Stevanato Group SpA is a leading player in the pharmaceutical packaging market, particularly for injectables. Its integrated solutions and focus on high-quality products provide a competitive edge. The company's growth is tied to the pharmaceutical industry, but its strategic initiatives and expansion into new markets offer opportunities for continued success. They need to watch out for the larger players in the market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data and analyst estimates are subject to change. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Stevanato Group SpA
Exchange NYSE | Headquaters Piombino Dese, PD, Italy | ||
IPO Launch date 2021-07-16 | CEO & Executive Chairman Mr. Franco Stevanato | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 5521 | Website https://www.stevanatogroup.com |
Full time employees 5521 | Website https://www.stevanatogroup.com | ||
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass forming machines; and after-sales services, such as spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug product, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.